Cancer drug tested against COVID-19 in small trial
NCT ID NCT04394416
First seen Mar 30, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This study tested whether imatinib, a cancer drug, could help hospitalized adults with COVID-19. It was a Phase 3 trial that planned to compare imatinib plus standard care to a placebo plus standard care, but it was stopped early after enrolling only 21 people. The main goal was to see if imatinib reduced deaths by day 28.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.